NovaBridge Biosciences Shareholder Approval Filed
Ticker: NBP · Form: 6-K · Filed: Oct 29, 2025 · CIK: 1778016
Sentiment: neutral
Topics: shareholder-approval, corporate-event, filing
TL;DR
NovaBridge shareholders approved a deal on Oct 24th. 6-K filed.
AI Summary
NovaBridge Biosciences filed a Form 6-K on October 29, 2025, reporting on events from October 2025. The filing indicates that on October 24, 2025, the company's shareholders approved a previously announced transaction. The company's principal executive offices are located at 2440 Research Boulevard, Suite 400, Rockville, MD 20850.
Why It Matters
This filing confirms shareholder approval for a significant corporate event, which could impact the company's future operations and stock value.
Risk Assessment
Risk Level: low — This filing is a routine report of shareholder approval for a previously announced transaction and does not introduce new material risks.
Key Players & Entities
- NovaBridge Biosciences (company) — Filer of the 6-K report
- October 24, 2025 (date) — Date of shareholder approval
- October 2025 (date) — Reporting period for the 6-K
- 2440 Research Boulevard, Suite 400, Rockville, MD 20850 (location) — Principal executive offices of NovaBridge Biosciences
FAQ
What specific transaction was approved by NovaBridge Biosciences' shareholders on October 24, 2025?
The filing states that shareholders approved a 'previously announced transaction' but does not specify the details of this transaction within the provided text.
What is the purpose of a Form 6-K filing?
A Form 6-K is a report of foreign private issuers pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934, used to report material information that is made public in their home country.
When was NovaBridge Biosciences previously known as I-Mab?
The company was formerly known as I-Mab, with a date of name change on May 28, 2019.
What is NovaBridge Biosciences' Standard Industrial Classification (SIC) code?
NovaBridge Biosciences' SIC code is 2834, which corresponds to Pharmaceutical Preparations.
Where are NovaBridge Biosciences' principal executive offices located?
The company's principal executive offices are located at 2440 Research Boulevard, Suite 400, Rockville, MD 20850.
Filing Stats: 434 words · 2 min read · ~1 pages · Grade level 11.5 · Accepted 2025-10-29 16:05:03
Filing Documents
- name_and_ticker_pr_10-29.htm (6-K) — 33KB
- imab-ex3_1.htm (EX-3.1) — 9KB
- imab-ex99_1.htm (EX-99.1) — 54KB
- img44095488_0.jpg (GRAPHIC) — 440KB
- img44095488_1.jpg (GRAPHIC) — 440KB
- img198603517_0.jpg (GRAPHIC) — 76KB
- img198603517_1.jpg (GRAPHIC) — 19KB
- img198603517_2.jpg (GRAPHIC) — 5KB
- 0001193125-25-256295.txt ( ) — 1447KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. NovaBridge Biosciences By : /s/ Xi-Yong Fu Name : Sean Fu Title : Chief Executive Officer Date: October 29, 2025